RxDoctor Payments Data

Judith Spieldenner

Family · Lexington, OHNPI 1467489823

Payments from drug & device makers

$856in general payments, 2019–2025

Across 44 payments — averaging $19.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$345
  • AbbVie$116
  • Bayer$97
  • Exact Sciences$51
  • Johnson & Johnson$44
  • GSK$41
  • plus $162 from 8 others

What the payments were for

  • Food & beverage$856100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$856 in reported general payments places this provider in the 65th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$46,008
Medicare patients
178
Services billed
687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$76,629
JardianceEmpagliflozin53$69,732
OzempicSemaglutide38$53,892
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$41,130
XareltoRivaroxaban14$12,511
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$8,499
Spiriva HandihalerTiotropium Bromide16$8,055
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$4,348
SymbicortBudesonide/Formoterol Fumarate19$4,221
Incruse ElliptaUmeclidinium Bromide12$3,553
Atorvastatin Calcium365$3,030
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$2,958
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,404
Lisinopril246$1,810
Levothyroxine Sodium227$1,757

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$76,62966 claims
Boehringer IngelheimJardiance$15$69,73253 claims
Novo NordiskOzempic$345$53,89238 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta$41$53,18271 claims
Johnson & JohnsonXarelto$44$12,51114 claims
AstraZenecaSymbicort$17$4,22119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,812 family providers in Ohio.

Other family in Lexington

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →